Clinical trial

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

NCT07465757

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Alisertib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-09-17

PhasePHASE2

Conditions

Small Cell Lung Cancer ( SCLC )unresolved

Interventions

AlisertibDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

Puma Biotechnology, Inc.lead sponsor

Mapped research locations

BarcelonaSpain2 SevilleSpain1 AlicanteSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07465757 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.